GlobeNewswire: ReNetx Bio Contains the last 10 of 6 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T00:57:58ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2020/01/08/1967900/0/en/ReNetX-Bio-Receives-Fast-Track-Designation-From-U-S-FDA.html?f=22&fvtc=4&fvtv=39463ReNetX Bio Receives Fast Track Designation From U.S. FDA2020-01-08T14:02:00Z<![CDATA[Potential First-in-Class Therapy for Chronic Spinal Cord Injury Potential First-in-Class Therapy for Chronic Spinal Cord Injury]]>https://www.globenewswire.com/news-release/2019/08/14/1901826/0/en/ReNetX-Bio-Announces-Initiation-of-Patient-Dosing-in-the-First-Phase-1-Clinical-Trial-of-Fusion-Protein-AXER-204.html?f=22&fvtc=4&fvtv=39463ReNetX Bio Announces Initiation of Patient Dosing in the First Phase 1 Clinical Trial of Fusion Protein AXER-2042019-08-14T13:02:00Z<![CDATA[NEW HAVEN, Conn., Aug. 14, 2019 (GLOBE NEWSWIRE) -- ReNetX Bio, Inc., a leading biotechnology company committed to reversing disease and damage for patients suffering from central nervous system (CNS) disorders, has announced a successful first patient dosing in a Phase 1 clinical trial of its lead drug candidate, fusion protein AXER-204.]]>https://www.globenewswire.com/news-release/2018/04/10/1467681/0/en/ReNetX-Bio-Invited-to-Present-Breakthrough-at-Leading-Spinal-Cord-Injury-Symposium.html?f=22&fvtc=4&fvtv=39463ReNetX Bio Invited to Present Breakthrough at Leading Spinal Cord Injury Symposium2018-04-10T12:00:00Z<![CDATA[NEW HAVEN, Conn., April 10, 2018 (GLOBE NEWSWIRE) -- Thanks to the promise of its NoGo Trap therapeutic for treating chronic spinal cord injury (SCI), New Haven-based startup ReNetX Bio has been invited to present as part of a “Clinical Trials 360” symposium at the upcoming American Spinal Cord Injury Association (ASIA) meeting. The NoGo Trap blocks inhibitors in the central nervous system thereby allowing the body to repair itself by re-growing nerve fiber connections. The company was invited “based on the promise and uniqueness of our treatment for spinal cord injury,” says ReNetX President and CSO George Maynard. Unlike many other treatments attempting to address acute injury, the NoGo Trap trial will focus on chronic patients who have an injury beyond one year. The breakthrough technology developed in Dr. Stephen Strittmatter’s laboratory at Yale has an entirely new approach that has shown successful restoration of neurons in animal studies many months after spinal cord injury.]]>https://www.globenewswire.com/news-release/2018/02/12/1339165/0/en/Remedy-Pharmaceuticals-Co-founder-and-CEO-Brings-Clinical-Trial-and-Company-Building-Experience-to-ReNetX-Bio-Advisory-Board.html?f=22&fvtc=4&fvtv=39463Remedy Pharmaceuticals Co-founder and CEO Brings Clinical Trial and Company-Building Experience to ReNetX Bio Advisory Board2018-02-12T15:00:00Z<![CDATA[NEW HAVEN, Conn., Feb. 12, 2018 (GLOBE NEWSWIRE) -- Sven Jacobson will be the first to admit that developing a new therapeutic for spinal cord injury is a challenging road. But the latest member of the ReNetX Advisory Board sees the promise of their first-in-class therapeutic in development to treat chronic spinal cord injury, and has the experience to help guide the clinical studies needed to move that drug forward.]]>https://www.globenewswire.com/news-release/2017/11/07/1176737/0/en/ReNetX-Bio-Receives-7M-Commitment-from-Wings-for-Life-to-Bring-Spinal-Cord-Treatment-to-Trial.html?f=22&fvtc=4&fvtv=39463ReNetX Bio Receives $7M Commitment from Wings for Life to Bring Spinal Cord Treatment to Trial2017-11-07T18:00:00Z<![CDATA[NEW HAVEN, Conn., Nov. 07, 2017 (GLOBE NEWSWIRE) -- The Wings for Life foundation has made a significant commitment to ReNetX Bio, a New-Haven, Conn. based biotech startup that is advancing a cutting-edge therapy for chronic spinal cord injury to clinical trial. The foundation’s support is a testament to the promising research results from ReNetX Founder and Scientific Advisor Stephen Strittmatter, MD, PhD, Vincent Coates Professor of Neurology at Yale. His discovery of proteins which limit nerve fiber growth after injury, and subsequent development of a molecule to block receptors for these proteins, have formed the basis of a therapeutic that offers the first real hope to patients with chronic spinal cord injury.]]>https://www.globenewswire.com/news-release/2017/10/10/1143937/0/en/Leading-Spinal-Cord-Injury-Experts-Join-ReNetX-Scientific-Advisory-Board.html?f=22&fvtc=4&fvtv=39463Leading Spinal Cord Injury Experts Join ReNetX Scientific Advisory Board2017-10-10T18:15:10Z<![CDATA[NEW HAVEN, Conn., Oct. 10, 2017 (GLOBE NEWSWIRE) -- ReNetX Bio, a company developing first-in-class therapeutics to treat injury to the central nervous system, is expanding its Scientific Advisory Board with key opinion leaders specializing in spinal cord injury. Andrew Blight, PhD, brings experience as the former Chief Scientific Officer of Acorda Therapeutics, Inc., where he helped move forward therapies for stroke and spinal cord injury (SCI) and ran two of the largest multicenter clinical trials in chronic SCI around the potassium channel blocker, 4-aminopyridine, which achieved FDA approval for the treatment of walking impairment in persons with multiple sclerosis. Blight also brings significant academic research experience, particularly surrounding the role of inflammation and demyelination in SCI, and held faculty roles at New York University Medical Center, Purdue University and the University of North Carolina where he was Professor and Director of the Neurosurgery Research Laboratory.]]>